Odyssey Therapeutics

ODTX · Nasdaq Filing snapshot

Odyssey Therapeutics is a clinical-stage biotech developing small-molecule medicines for inflammatory and autoimmune diseases. Its lead candidate, OD-001, is an oral scaffolding inhibitor of RIPK2 for inflammatory bowel disease (IBD). The company has not generated revenue. Its $18.00 Nasdaq IPO raised about $279M gross. The filing names a deep field: other RIPK2 programs (GSK, Novartis, Bristol Myers Squibb, plus Accro Bioscience, Oncodesign, Vibliome and Zenitar) and, in IBD, marketed drugs from AbbVie (Humira, Skyrizi, Rinvoq), J&J (Remicade, Simponi, Stelara), Eli Lilly (Omvoh), Takeda (Entyvio) and Pfizer (Xeljanz, Velsipity).

Listed

May 08, 2026

Raised

$279M

Sector

Biotechnology · Immunology · Inflammation

Named rivals

14 in the S-1

Named in the S-1 12 of 14 shown

Odyssey Therapeutics

ODTX · the filer

AbbVie

named 3×

Johnson & Johnson

named 3×

Pfizer

named 2×

Bristol Myers Squibb

named 2×

Takeda

named 2×

Eli Lilly

named 1×

Novartis

named 1×

GSK

named 1×

Accro Bioscience

named 1×

Oncodesign

named 1×

Vibliome Therapeutics

named 1×

Zenitar Biomedical

named 1×

“

The read

Its lead RIPK2 inhibitor (OD-001) faces a two-layer field: a pack of RIPK2 developers — GSK, Novartis, BMS, plus startups like Vibliome and Accro — and, in IBD, the marketed establishment: AbbVie's Humira/Skyrizi/Rinvoq, J&J's Stelara, Lilly's Omvoh, Takeda's Entyvio. 14 named rivals; no revenue yet.

Want the full picture on Odyssey Therapeutics?

Request the deep Exposure Report — share-of-presence, a 90-day signal timeline, and the white space these 14 rivals leave open. We build it within 48 hours.

Request full coverage